Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131326 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00131326 is a Phase 3 study that has completed, run by Genzyme, a Sanofi Company.
The verdict
NCT00131326, a Phase 3 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
This is a clinical study to investigate the safety and efficacy of Synvisc and Depo-Medrol in treating patients with osteoarthritis (OA) of the hip.
Interventions
- DEVICE Synvisc (hylan G-F 20)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-11 |
| Est. Completion | 2006-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00131326
The ClinicalTrials.gov registry entry for NCT00131326 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Synvisc (hylan G-F 20) is the first listed.
NCT00131326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00131326 about?
NCT00131326 is a clinical study titled "A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip". This is a clinical study to investigate the safety and efficacy of Synvisc and Depo-Medrol in treating patients with osteoarthritis (OA) of the hip.
What is the current status of trial NCT00131326?
This trial is currently completed. It is a Phase 3 study. The study started on 2003-11. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00131326?
The interventions under investigation include: Synvisc (hylan G-F 20) (DEVICE).
Who is sponsoring clinical trial NCT00131326?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.